These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 31895562)

  • 21. Cdc7 kinase inhibitors: pyrrolopyridinones as potential antitumor agents. 1. Synthesis and structure-activity relationships.
    Vanotti E; Amici R; Bargiotti A; Berthelsen J; Bosotti R; Ciavolella A; Cirla A; Cristiani C; D'Alessio R; Forte B; Isacchi A; Martina K; Menichincheri M; Molinari A; Montagnoli A; Orsini P; Pillan A; Roletto F; Scolaro A; Tibolla M; Valsasina B; Varasi M; Volpi D; Santocanale C
    J Med Chem; 2008 Feb; 51(3):487-501. PubMed ID: 18201066
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Design and Optimization Leading to an Orally Active TTK Protein Kinase Inhibitor with Robust Single Agent Efficacy.
    Riggs JR; Elsner J; Cashion D; Robinson D; Tehrani L; Nagy M; Fultz KE; Krishna Narla R; Peng X; Tran T; Kulkarni A; Bahmanyar S; Condroski K; Pagarigan B; Fenalti G; LeBrun L; Leftheris K; Zhu D; Boylan JF
    J Med Chem; 2019 May; 62(9):4401-4410. PubMed ID: 30998356
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Development of Potent Pyrazolopyrimidinone-Based WEE1 Inhibitors with Limited Single-Agent Cytotoxicity for Cancer Therapy.
    Matheson CJ; Casalvieri KA; Backos DS; Reigan P
    ChemMedChem; 2018 Aug; 13(16):1681-1694. PubMed ID: 29883531
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A Cdc7 kinase inhibitor restricts initiation of DNA replication and has antitumor activity.
    Montagnoli A; Valsasina B; Croci V; Menichincheri M; Rainoldi S; Marchesi V; Tibolla M; Tenca P; Brotherton D; Albanese C; Patton V; Alzani R; Ciavolella A; Sola F; Molinari A; Volpi D; Avanzi N; Fiorentini F; Cattoni M; Healy S; Ballinari D; Pesenti E; Isacchi A; Moll J; Bensimon A; Vanotti E; Santocanale C
    Nat Chem Biol; 2008 Jun; 4(6):357-65. PubMed ID: 18469809
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Design, synthesis, and evaluation of non-ATP-competitive small-molecule Polo-like kinase 1 (Plk1) inhibitors.
    Chen DX; Huang J; Liu M; Xu YG; Jiang C
    Arch Pharm (Weinheim); 2015 Jan; 348(1):2-9. PubMed ID: 25430493
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cdc7 kinase inhibitors: 5-heteroaryl-3-carboxamido-2-aryl pyrroles as potential antitumor agents. 1. Lead finding.
    Menichincheri M; Albanese C; Alli C; Ballinari D; Bargiotti A; Caldarelli M; Ciavolella A; Cirla A; Colombo M; Colotta F; Croci V; D'Alessio R; D'Anello M; Ermoli A; Fiorentini F; Forte B; Galvani A; Giordano P; Isacchi A; Martina K; Molinari A; Moll JK; Montagnoli A; Orsini P; Orzi F; Pesenti E; Pillan A; Roletto F; Scolaro A; Tatò M; Tibolla M; Valsasina B; Varasi M; Vianello P; Volpi D; Santocanale C; Vanotti E
    J Med Chem; 2010 Oct; 53(20):7296-315. PubMed ID: 20873740
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Structure-based Design of Pyridone-Aminal eFT508 Targeting Dysregulated Translation by Selective Mitogen-activated Protein Kinase Interacting Kinases 1 and 2 (MNK1/2) Inhibition.
    Reich SH; Sprengeler PA; Chiang GG; Appleman JR; Chen J; Clarine J; Eam B; Ernst JT; Han Q; Goel VK; Han EZR; Huang V; Hung INJ; Jemison A; Jessen KA; Molter J; Murphy D; Neal M; Parker GS; Shaghafi M; Sperry S; Staunton J; Stumpf CR; Thompson PA; Tran C; Webber SE; Wegerski CJ; Zheng H; Webster KR
    J Med Chem; 2018 Apr; 61(8):3516-3540. PubMed ID: 29526098
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Discovery of 4-{4-[(3R)-3-Methylmorpholin-4-yl]-6-[1-(methylsulfonyl)cyclopropyl]pyrimidin-2-yl}-1H-indole (AZ20): a potent and selective inhibitor of ATR protein kinase with monotherapy in vivo antitumor activity.
    Foote KM; Blades K; Cronin A; Fillery S; Guichard SS; Hassall L; Hickson I; Jacq X; Jewsbury PJ; McGuire TM; Nissink JW; Odedra R; Page K; Perkins P; Suleman A; Tam K; Thommes P; Broadhurst R; Wood C
    J Med Chem; 2013 Mar; 56(5):2125-38. PubMed ID: 23394205
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Discovery of novel furanone derivatives as potent Cdc7 kinase inhibitors.
    Irie T; Asami T; Sawa A; Uno Y; Hanada M; Taniyama C; Funakoshi Y; Masai H; Sawa M
    Eur J Med Chem; 2017 Apr; 130():406-418. PubMed ID: 28279847
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Structure-based design, SAR analysis and antitumor activity of PI3K/mTOR dual inhibitors from 4-methylpyridopyrimidinone series.
    Cheng H; Hoffman JE; Le PT; Pairish M; Kania R; Farrell W; Bagrodia S; Yuan J; Sun S; Zhang E; Xiang C; Dalvie D; Rahavendran SV
    Bioorg Med Chem Lett; 2013 May; 23(9):2787-92. PubMed ID: 23506825
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Discovery of 4-(4-aminopyrazolo[1,5-a][1,3,5]triazin-8-yl)benzamides as novel, highly potent and selective, orally bioavailable inhibitors of Tyrosine Threonine Kinase, TTK.
    Laufer R; Li SW; Liu Y; Ng G; Lang Y; Feher M; Brokx R; Beletskaya I; Hodgson R; Mao G; Plotnikova O; Awrey DE; Mason JM; Wei X; Lin DC; Che Y; Kiarash R; Madeira B; Fletcher GC; Mak TW; Bray MR; Pauls HW
    Bioorg Med Chem Lett; 2016 Aug; 26(15):3562-6. PubMed ID: 27335255
    [TBL] [Abstract][Full Text] [Related]  

  • 32. First Cdc7 kinase inhibitors: pyrrolopyridinones as potent and orally active antitumor agents. 2. Lead discovery.
    Menichincheri M; Bargiotti A; Berthelsen J; Bertrand JA; Bossi R; Ciavolella A; Cirla A; Cristiani C; Croci V; D'Alessio R; Fasolini M; Fiorentini F; Forte B; Isacchi A; Martina K; Molinari A; Montagnoli A; Orsini P; Orzi F; Pesenti E; Pezzetta D; Pillan A; Poggesi I; Roletto F; Scolaro A; Tatò M; Tibolla M; Valsasina B; Varasi M; Volpi D; Santocanale C; Vanotti E
    J Med Chem; 2009 Jan; 52(2):293-307. PubMed ID: 19115845
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Discovery of 3H-benzo[4,5]thieno[3,2-d]pyrimidin-4-ones as potent, highly selective, and orally bioavailable inhibitors of the human protooncogene proviral insertion site in moloney murine leukemia virus (PIM) kinases.
    Tao ZF; Hasvold LA; Leverson JD; Han EK; Guan R; Johnson EF; Stoll VS; Stewart KD; Stamper G; Soni N; Bouska JJ; Luo Y; Sowin TJ; Lin NH; Giranda VS; Rosenberg SH; Penning TD
    J Med Chem; 2009 Nov; 52(21):6621-36. PubMed ID: 19842661
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Imidazopyridine derivatives as potent and selective Polo-like kinase (PLK) inhibitors.
    Sato Y; Onozaki Y; Sugimoto T; Kurihara H; Kamijo K; Kadowaki C; Tsujino T; Watanabe A; Otsuki S; Mitsuya M; Iida M; Haze K; Machida T; Nakatsuru Y; Komatani H; Kotani H; Iwasawa Y
    Bioorg Med Chem Lett; 2009 Aug; 19(16):4673-8. PubMed ID: 19589677
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Discovery and SARs of 5-Chloro-
    Wang Y; Chen X; Yan Y; Zhu X; Liu M; Liu X
    J Med Chem; 2020 Mar; 63(6):3327-3347. PubMed ID: 32129996
    [TBL] [Abstract][Full Text] [Related]  

  • 36. 4-(1H-indazol-5-yl)-6-phenylpyrimidin-2(1H)-one analogs as potent CDC7 inhibitors.
    Shafer CM; Lindvall M; Bellamacina C; Gesner TG; Yabannavar A; Jia W; Lin S; Walter A
    Bioorg Med Chem Lett; 2008 Aug; 18(16):4482-5. PubMed ID: 18672368
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Synthesis and anti-tumor efficacy of novel 2, 4-diarylaminopyrimidine derivatives bearing N-(3-pyridinylmethyl) urea moiety as anaplastic lymphoma kinase inhibitors.
    Chen H; Li R; Ning X; Zhao X; Jin Y; Yin Y
    Eur J Med Chem; 2019 Sep; 178():141-153. PubMed ID: 31177074
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Synthesis and structure-activity relationships of a novel series of pyrimidines as potent inhibitors of TBK1/IKKε kinases.
    McIver EG; Bryans J; Birchall K; Chugh J; Drake T; Lewis SJ; Osborne J; Smiljanic-Hurley E; Tsang W; Kamal A; Levy A; Newman M; Taylor D; Arthur JS; Clark K; Cohen P
    Bioorg Med Chem Lett; 2012 Dec; 22(23):7169-73. PubMed ID: 23099093
    [TBL] [Abstract][Full Text] [Related]  

  • 39. X-ray Crystal Structure-Guided Design and Optimization of 7
    Lee Y; Kim H; Kim H; Cho HY; Jee JG; Seo KA; Son JB; Ko E; Choi HG; Kim ND; Kim I
    J Med Chem; 2021 May; 64(10):6985-6995. PubMed ID: 33942608
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    Yang T; Hu M; Chen Y; Xiang M; Tang M; Qi W; Shi M; He J; Yuan X; Zhang C; Liu K; Li J; Yang Z; Chen L
    J Med Chem; 2020 Dec; 63(23):14921-14936. PubMed ID: 33256400
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.